CADL vs. ORIC, AMLX, MAZE, SION, PHAR, TRVI, ATAI, SPRY, CRON, and CRMD
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Oric Pharmaceuticals (ORIC), Amylyx Pharmaceuticals (AMLX), Maze Therapeutics (MAZE), Sionna Therapeutics (SION), Pharming Group (PHAR), Trevi Therapeutics (TRVI), atai Life Sciences (ATAI), ARS Pharmaceuticals (SPRY), Cronos Group (CRON), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.
Candel Therapeutics vs. Its Competitors
Candel Therapeutics (NASDAQ:CADL) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Candel Therapeutics has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
Candel Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Candel Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Candel Therapeutics had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Candel Therapeutics and 3 mentions for Oric Pharmaceuticals. Candel Therapeutics' average media sentiment score of 1.21 beat Oric Pharmaceuticals' score of 0.51 indicating that Candel Therapeutics is being referred to more favorably in the media.
Candel Therapeutics' return on equity of -41.00% beat Oric Pharmaceuticals' return on equity.
13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by company insiders. Comparatively, 5.6% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Candel Therapeutics currently has a consensus target price of $20.00, indicating a potential upside of 315.80%. Oric Pharmaceuticals has a consensus target price of $17.29, indicating a potential upside of 63.69%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Candel Therapeutics is more favorable than Oric Pharmaceuticals.
Summary
Candel Therapeutics beats Oric Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CADL) was last updated on 9/22/2025 by MarketBeat.com Staff
Free CADL Stock Alerts